Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II randomised, double-blind, controlled study to evaluate the safety and efficacy of PROSTVAC-VF/TRICOM in combination with GM-CSF [granulocyte-macrophage colony-stimulating factors] in patients with androgen-independent adenocarcinoma of the prostate

Next Previous
Trial Profile

A phase II randomised, double-blind, controlled study to evaluate the safety and efficacy of PROSTVAC-VF/TRICOM in combination with GM-CSF [granulocyte-macrophage colony-stimulating factors] in patients with androgen-independent adenocarcinoma of the prostate

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 30 May 2014 Results on immune response presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
  • 28 Jul 2011 Results have been reported in Vaccine, according to a Bavarian Nordic media release.
  • 30 Apr 2010 On the basis of these trial results, PROSTVAC has been granted Fast Track status by the FDA for the treatment of men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top